Across TCGA pan-cancer cohorts, BRI3BP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BRI3BP data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BRI3BP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BRI3BP expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where BRI3BP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.680	0.923	.003	25	view →
PDAC	OS	Tertile	III,IV	0.602	0.230	.010	25	view →
LSCC	OS	Quartile	II,III,IV	0.905	0.607	.009	14	view →
UCEC	OS	Tertile	III,IV	0.347	0.807	.042	4	view →
LUAD	DFS	Tertile	All	0.400	0.722	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BRI3BP tumor-vs-normal RNA expression · all BRI3BP data types